How to Manage Injectable Stock in Your Aesthetic Clinic (Batch Tracking & Expiry)

Injectable stock management is one of the areas where aesthetic clinic admin most directly intersects with clinical safety and regulatory compliance. It is also one of the areas where clinics most commonly rely on informal systems — a spreadsheet, a paper stock sheet, or pure memory — until an inspection, an adverse event, or a product recall forces a rethink.

This guide covers what proper injectable stock management looks like for an aesthetic clinic: what batch tracking means, why expiry management is more complex than it sounds, what your goods received records should contain, and what CQC inspectors and the MHRA expect to see. It also covers the US equivalent requirements for medspas, and how software makes all of this manageable without dedicated admin time.

Why injectable stock management is a compliance requirement, not just admin

In the UK, aesthetic injectables — Botox, botulinum toxins, and most dermal fillers — are either prescription-only medicines (POMs) or Class III medical devices, depending on their composition. This places them under the oversight of the MHRA (Medicines and Healthcare products Regulatory Agency) and, for CQC-registered clinics, within the scope of CQC inspection.

The MHRA requires that any organisation handling POMs maintains accurate records of:

• What was purchased, from which supplier, in what quantity
• The batch number and expiry date of every unit received
• How each unit was used, stored, and disposed of
• Any adverse events associated with a specific batch.

For CQC-registered clinics, the Safe domain of inspection specifically covers medicines management. Inspectors will ask to see stock records, purchase records, and — critically — how the clinic would identify which patients were treated with a recalled product batch if a recall was issued. Without batch-level records linked to patient treatment notes, this is impossible to answer.

In the US, the FDA and DEA have equivalent requirements for prescription medications used in medspa settings. HIPAA also requires that patient records reflect which specific products were used in treatment, supporting traceability in the event of an adverse event or recall.

What batch tracking actually means

Batch tracking is not simply counting units. It means recording, for every vial or syringe used in a treatment:

• The batch number: the unique identifier assigned by the manufacturer to a production run
• The expiry date: the date after which the product should not be used — not the opening date, and not a guess
• The quantity used: how many units were administered, so the remaining balance in the vial is accurately tracked
• The patient: which patient received product from this batch
• The practitioner: who administered it
• The date: when it was used

When this information is linked — a batch number maps to a product, which maps to the patients treated and the practitioner who administered it — you can answer a product recall within minutes rather than hours. “Which patients were treated with Bocouture batch X12345 between January and March?” becomes a database query, not a manual search through paper records.

Consentz’s stock module records batch numbers and links each treatment to the stock used — automatically deducting from the batch balance when a practitioner records a treatment, and flagging when a batch is approaching expiry. For the related documentation around prescribing and medicines administration, see our guide on prescription management for aesthetic clinics.

Expiry date management — more complex than it looks

Expiry management in aesthetics is complicated by a few factors that do not apply to most product stock:

Multi-stage expiry: manufacturer expiry versus reconstituted expiry

Botulinum toxins (Botox, Azzalure, Bocouture etc.) have a manufacturer expiry date printed on the vial — typically 36 months from manufacture. But once the product is reconstituted (mixed with saline for injection), the effective shelf life drops to 4–24 hours depending on the product and your storage protocol. Your stock records need to capture both the manufacturer expiry and the reconstitution window.

Partial use and wastage

A 100-unit vial of botulinum toxin used across two patients in a session will leave a partial-use balance. That remaining product needs to be either used within the reconstituted window or disposed of as clinical waste — and the wastage recorded. Wastage records matter for CQC inspection (they demonstrate controlled disposal) and for understanding your true cost per unit.

Cold chain compliance

Most botulinum toxins and some dermal fillers require refrigerated storage at specific temperatures (typically 2–8°C). Cold chain compliance — maintaining and recording that temperature throughout the storage period — is a MHRA requirement for POMs and an expected standard for other injectables. Your stock records should note that products were stored correctly, particularly for stock held for extended periods.

Goods received records — what they need to contain

Every delivery of injectable product should be recorded immediately on receipt. Your goods received record should capture:

• Date of delivery
• Supplier name and invoice or order number
• Product name and brand (specific, not generic — “Azzalure 125u” not just “Botox”)
• Quantity received
• Batch number from the packaging
• Expiry date from the packaging
• Condition on arrival (packaging intact, cold chain maintained, no damage)
• Who received and checked the delivery

This process takes under two minutes per delivery when it is built into your workflow. It takes several hours if you ever need to reconstruct it from memory or invoices during an inspection.

For a comprehensive overview of CQC documentation requirements, see the CQC compliance documentation toolkit for aesthetic clinics. For the broader picture on what CQC inspectors expect, the CQC compliance guides cover the key areas in detail.

How to handle a product recall

MHRA product recalls in aesthetics do happen — botulinum toxin batches, filler products, and associated consumables have all been subject to recalls in recent years. When a recall is issued, the MHRA expects you to:

• Identify whether you hold or have used the recalled product batch
• Quarantine any remaining stock immediately if applicable
• Contact any patients treated with product from the recalled batch
• Return or dispose of remaining stock as directed
• Document the action taken and report to the MHRA if required

Without batch-level records linked to patient notes, step 3 — identifying and contacting affected patients — cannot be completed accurately or quickly. With proper batch tracking in your clinic software, you run a single query and have the patient list within seconds.

Frequently asked questions